Cancer Clinical Trials & Research

About cCARE’s cancer research

cCARE is proud to offer numerous institutional-grade clinical trials for cancer patients. Clinical trials assess new drug or treatment effectiveness and provide cancer patients with the newest – and possibly most effective – forms of treatment.

Cancer clinical trials are divided into three different phases. Phase I trials assess the safety of a drug or treatment; phase II trials quantify how effective the treatment is while phase III compares the trial to the best existing cancer treatment.

The decision to participate in a cancer clinical trial should be made early in the diagnosis stage because once treatment begins, patients may not be eligible to participate in certain clinical trials. Benefits of participating in cancer clinical trials include access to the newest treatment and medicine designed to fight your particular type of cancer as well as being monitored closely throughout the treatment process.

Although clinical trials provide many benefits, patients must consider the risks as well. Participants may experience unforeseen side effects, the treatment may just not work as well as previous methods and health insurance coverage may not extend to participating in a trial. Speak with your oncologist about whether or not a clinical trial is right for your specific case.

Open cancer clinical trials at cCARE

Below is a list of cancer clinical trials currently open at cCARE. If you have any questions please call us at (760) 452-3909 or email Beth Kimball, RN OCN, Clinical Research Manager, at [email protected].

 

San Diego cancer clinical trials – (jump to Fresno clinical trials)

Non Hodgkin Lymphoma Clinical Trial

Title: Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE)

This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with CD 20 positive B-cell non Hodgkin lymphoma. This study will assess if the investigational medicine is safe and effective in treating CD 20 positive B-cell non Hodgkin lymphoma.

Learn More About This Cancer Study


Advanced or Metastatic Solid Tumors Clinical Trial

Title: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti programmed death receptor 1 (anti-PD-1) antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion.

Learn More About This Cancer Study


Melanoma Clinical Trial

Title: Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)

Phase 1b Subjects will be treated with talimogene laherparepvec until all injectable tumors have disappeared, disease progression per modified Immune-Related Response Criteria (irRC), or intolerance of study treatment, up to a maximum of 24 months of study treatment. Subjects will be treated with MK-3475 (pembrolizumab) until complete response (CR) disease progression per irRC, or intolerance of study treatment, up to a maximum of 24 months of study treatment. In Phase 3, Subjects will be treated with talimogene laherparepvec plus pembrolizumab(arm 1) or placebo plus pembrolizumab (arm 2) until 24 months from the date of the first dose of pembrolizumab or end of treatment due to disappearance of injectable lesions, complete response, disease progression per irRC-RECIST or intolerance of study treatment.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint is to determine the optimal dose of radium-223 dichloride in combination with bortezomib/dexamethasone for the Phase 2 portion of the study.

The phase 2 part will be an international, phase 2, double-blind, randomized, placebo-controlled assessment of radium-223 dichloride versus placebo administered with bortezomib and dexamethasone, in subjects with relapsed multiple myeloma.

Learn More About This Cancer Study


Advanced and Metastatic Breast Cancer Clinical Trial

Title: Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR)

This dose finding/extension study consists of three parts: Part A will identify the MTD of the AZD2014/palbociclib combination on a background of fulvestrant (referred to as the triplet) in postmenopausal women with locally advanced/metastatic estrogen receptor positive (ER+) breast cancer. Part B will further characterize safety, tolerability, PK, and preliminary efficacy in single-arm dose expansion groups. Part C will investigate the efficacy of the triplet combination in a double-blind, placebo-controlled, stratified, parallel group extension.

Learn More About This Cancer Study


Gastric Cancer Clinical Trial

Title: Avelumab in First-Line Gastric Cancer

The purpose of this study is to demonstrate superiority of treatment with Avelumab versus continuation of first-line chemotherapy.

Learn More About This Cancer Study


Cancer Tumors Clinical Trial

Title: MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals.

Learn More About This Cancer Study


Solid Tumors, Non-Small Cell Lung, Biliary & Bladder Cancer Clinical Trial

Title: Combination Therapy with NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

In the dose escalation phase (Part 1), this study will determine the dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) and recommended Phase 2 (RPII) dose of NC 6004 in combination with gemcitabine.

Learn More About This Cancer Study


Glioblastoma Multiforme Clinical Trial

Title: A Feasibility Study of the Nativis Voyager System in Patients with Recurrent Glioblastoma Multiforme (GBM)

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 64 subjects of which 32 will be treated with the Voyager therapy alone (monotherapy) and 32 will be treated with Voyager plus concurrent chemotherapy.

Learn More About This Cancer Study


Metastatic Castrate Resistant Prostate Cancer Clinical Trial

Title: Phase III Study of DCVAC Added to Standard Chemotherapy for Men with Metastatic Castration Resistant Prostate Cancer (VIABLE)

The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are currently showing progressive disease (worsening) and had progressed (did not respond to treatment) within 8 weeks of receiving treatment with 27mg/m2 of carfilzomib.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Pomalidomide for Lenalidomide for Failures

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM).

Learn More About This Cancer Study


Non-Small Cell Lung Cancer Clinical Trial

Title: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients with Lung Cancer [IMpower010]

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer.

Learn More About This Cancer Study


Hepatocellular Carcinoma Clinical Trial

Title: A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.

Learn More About This Cancer Study


Lung Cancer Clinical Trial

Title: Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab

This is a phase 1b study evaluating a combination of PEGPH20 and pembrolizumab for subjects with relapsed/refractory advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have failed at least 1 platinum-based chemotherapy regimen and subjects with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma after failing at least 1 chemotherapy regimen.

Learn More About This Cancer Study

Fresno cancer clinical trials – (jump to San Diego clinical trials)

Metastatic Colorectal Cancer Clinical Trial

Title: A Phase III Study of Xilonix in Patients with Advanced Colorectal Cancer (XCITE)

The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix (MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard therapy.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trials

Title: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma.

Learn More About This Cancer Study


Colorectal Cancer & Breast Cancer Clinical Trial

Title: Safety and Tolerability Study in Solid Tumors

This is an open-label, multicenter, sequential dose-escalation, and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GS-5745 alone and in combination with chemotherapy.

Learn More About This Cancer Study